| Accession |
PRJCA024566 |
| Title |
A study to evaluate the efficacy and safety of JS002 in patients with heterozygous familial hypercholesterolemia (HeFH). |
| Relevance |
Medical |
| Data types |
Exome
|
| Organisms |
Homo sapiens
|
| Description |
This Phase 3 trial is designed to evaluate the efficacy and safety of ongericimab, a novel monoclonal antibody targeting the anterior protein convertase subtilisin/kexin type 9 (PCSK9)), in Chinese patients with HeFH. |
| Sample scope |
Multiisolate |
| Release date |
2024-04-12 |
| Grants |
| Agency |
program |
Grant ID |
Grant title |
| Shanghai Junshi Biosciences Co., Ltd.
|
|
NA
|
|
|
|
| Submitter |
Yu
Hao (yu_hao@junshipharma.com)
|
| Organization |
Shanghai Junshi Biosciences Co., Ltd. |
| Submission date |
2024-03-21 |
